Please upgrade your browser.
Biotech company Aveo Pharmaceuticals Inc will pay $4 million to settle civil charges that it misled investors about U.S. regulators' concerns about its drug to treat kidney cancer...
We recently participated in Mediaplanet USA’s Kidney and Liver campaign in which the industry united to raise awareness about the often times difficult-to-detect, kidney or liver diseases that are steadily turning into a silent epidemic here in the United States. The campaign discusses the different types of kidney and liver diseases and how Americans can take a more proactive approach to ensuring they are not at risk. The special report was distributed through USA Today on March 29th, 2016 and is published online. Learn more: http://bit.ly/1SrdBed
The Department of Defense Peer Reviewed Cancer Research Program (PRCRP) has $50 Million dollars to invest for FY2016. One of the cancers they would like to have better represented among the proposals received is kidney cancer. There are multiple award mechanisms including a translational science team award for $1 million dollars.
Seven new medicines have been approved since 2005 for advanced kidney cancer...
The average age at diagnosis is 64 in whites, in whom kidney cancer is rare under age 45. However, in Nigeria, kidney cancer tends to occur earlier, with the average age of occurrence being in the forties.
Tweaking cholesterol levels with a simple pill may boost the effectiveness of new immunotherapy drugs that are starting to revolutionize the treatment of cancers, experiments in mice suggest.
A comprehensive molecular analysis of 894 primary renal cell carcinomas resulted in nine subtypes defined by systematic analysis of five genomic data platforms. Each major histologic types represent substantial molecular diversity.
The research project consists of a one-time telephone interview lasting 60 minutes. In appreciation of your time and valuable contribution, you will receive an honorarium of $200 payable upon successful completion of the telephone interview.
Adding core-needle biopsy to other clinical care may help improve outcomes for some patients with renal cell carcinoma...
Programmed death ligand 1 (PD-L1) expressed on the tumour cell surface, or on neighbouring host immune cells in the tumour microenvironment, engages the programmed death 1 (PD-1) receptor on activated cytotoxic T cells and thus downregulates the tumour-directed host immune response.
|Powered by NeonCRM|